Mitomicina Accord (Mitomycin)

Mitomycin, the active ingredient in Mitomicina Accord, is an antineoplastic (alkylating agent) presented as an injectable solution for intravenous use. It is employed in the treatment of various solid tumours, where it acts by interfering with DNA replication in rapidly dividing cancer cells.

GNH USA supplies Mitomicina Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Mitomicina Accord is an alkylating chemotherapy used for solid tumour management across several organ sites. - Bladder cancer: reduces tumour recurrence when administered intravesically after transurethral resection. - Gastric cancer: contributes to tumour control as part of combination regimens for advanced disease. - Anal canal carcinoma: enhances response when combined with 5‑fluorouracil and radiation in squamous cell carcinoma. - Non‑small cell lung cancer: adds cytotoxic effect within multi‑drug protocols for metastatic disease.

Mitomicina Accord may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring during or after infusion. - Myelosuppression: reduced white blood cells, platelets, and red cells. - Mucositis: inflammation of the oral and gastrointestinal mucosa. - Fatigue: generalized tiredness often reported during treatment cycles. - Renal toxicity: transient increases in serum creatinine.

Serious or Rare Side Effects: - Pulmonary fibrosis: progressive scarring of lung tissue. - Severe hemorrhagic cystitis: painful bladder bleeding, especially with intravesical use. - Cardiotoxicity: rare impairment of cardiac function. - Anaphylactic reactions: acute hypersensitivity during infusion. - Secondary malignancies: potential induction of new cancers after prolonged exposure.

Mitomicina Accord requires careful monitoring and adherence to safety guidelines. - Hematologic monitoring: perform regular complete blood counts to detect myelosuppression. - Renal function: assess serum creatinine and urine output before each dose. - Pulmonary assessment: evaluate lung function in patients with pre‑existing respiratory disease. - Bladder protection: consider co‑administration of mesna or adequate hydration for intravesical therapy. - Pregnancy and lactation: avoid use in pregnant or breastfeeding individuals unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mitomicina Accord can interact with several concomitant medications, influencing efficacy or toxicity.

Major Interactions (Avoid): - Anticoagulants: increased risk of bleeding. - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): additive renal impairment. - Other alkylating agents: heightened myelosuppression.

Moderate Interactions (Monitor Closely): - CYP450 inducers (e.g., rifampin): possible reduction in drug exposure. - Drugs affecting urinary pH (e.g., sodium bicarbonate): may alter bladder toxicity risk. - Immunosuppressants: enhanced infection susceptibility.